| Autor: |
Tessa Noordermeer, Roger E. G. Schutgens, Chantal Visser, Emma Rademaker, Moniek P. M. deMaat, A. J. Gerard Jansen, Maarten Limper, Olaf L. Cremer, Marieke J. H. A. Kruip, Henrik Endeman, Coen Maas, Bas deLaat, Rolf T. Urbanus, the Dutch COVID & Thrombosis Coalition (DCTC) |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2475-0379 |
| DOI: |
10.1002/rth2.12809 |
| Popis: |
Abstract Background Thrombosis is a frequent and severe complication in patients with coronavirus disease 2019 (COVID‐19) admitted to the intensive care unit (ICU). Lupus anticoagulant (LA) is a strong acquired risk factor for thrombosis in various diseases and is frequently observed in patients with COVID‐19. Whether LA is associated with thrombosis in patients with severe COVID‐19 is currently unclear. Objective To investigate if LA is associated with thrombosis in critically ill patients with COVID‐19. Patients/Methods The presence of LA and other antiphospholipid antibodies was assessed in patients with COVID‐19 admitted to the ICU. LA was determined with dilute Russell's viper venom time (dRVVT) and LA‐sensitive activated partial thromboplastin time (aPTT) reagents. Results Of 169 patients with COVID‐19, 116 (69%) tested positive for at least one antiphospholipid antibody upon admission to the ICU. Forty (24%) patients tested positive for LA; of whom 29 (17%) tested positive with a dRVVT, 19 (11%) tested positive with an LA‐sensitive aPTT, and 8 (5%) tested positive on both tests. Fifty‐eight (34%) patients developed thrombosis after ICU admission. The odds ratio (OR) for thrombosis in patients with LA based on a dRVVT was 2.5 (95% confidence interval [CI], 1.1–5.7), which increased to 4.5 (95% CI, 1.4–14.3) in patients at or below the median age in this study (64 years). LA positivity based on a dRVVT or LA‐sensitive aPTT was only associated with thrombosis in patients aged less than 65 years (OR, 3.8; 95% CI, 1.3–11.4) and disappeared after adjustment for C‐reactive protein. Conclusion Lupus anticoagulant on admission is strongly associated with thrombosis in critically ill patients with COVID‐19, especially in patients aged less than 65 years. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text